Product logins

Find logins to all Clarivate products below.


Multiple Sclerosis – Current Treatment – Current Treatment: Physician Insights – Multiple Sclerosis (EU5)

Numerous disease-modifying therapies (DMTs) have entered the multiple sclerosis (MS) disease landscape in recent years, many of them next-generation alternatives within existing classes. Most recently, TG Therapeutics launched Briumvi, the third-in-class anti-CD20 monoclonal antibody and Sandoz launched Tyruko, the first biosimilar for MS. Given the rapid pace of expansion in the MS market, developers of both current and emerging DMTs must continually reassess their products’ differentiation and positioning in this highly competitive space. This report will explore neurologists’ perceptions of established and recently launched DMTs, their prescribing habits in today’s market, and anticipated changes in brand usage as DMT choices expand—and further complicate—prescribing decisions.

Questions Answered

  • How are different MS subpopulations (i.e., clinically isolated syndrome, relapsing-remitting MS, secondary-progressive MS, and primary-progressive MS) treated?
  • How do product shares differ across lines of therapy? Which high-efficacy therapies (e.g., Ocrevus) are factoring into early-line treatment decisions?
  • What percentage of MS patients have experienced a relapse or disability progression in the past year? What percentage have nonrelapsing SP-MS?
  • How have neurologists’ prescribing changed in the past year, and why? What further changes do they expect within the next year?
  • What are neurologists’ opinions on the newest entrants in the MS market, and how are they incorporating these DMTs in the treatment paradigm?

Product Description

Through survey data from EU5 physicians, Current Treatment: Physician Insights offers in-depth analyses of the reasons behind treatment dynamics, prescribing behavior, and brand preference, enabling you to:

  • Understand the treatment landscape for a disease and how physicians make prescribing decisions.
  • Evaluate the drivers and obstacles that influence treatment selection.
  • Analyze your brand’s performance from the physician perspective to enhance or defend your competitive position.
  • Create impactful messaging for physicians by identifying brand differentiators and understanding what motivates prescribing behaviors.

Markets Covered: France, Germany, Italy, Spain, and the United Kingdom.

Primary research: Survey of 50 neurologists in France, Germany, Italy, Spain, and the United Kingdom.

Key drugs covered: Ocrevus, Kesimpta, Briumvi, Tysabri, Tyruko, fingolimod, teriflunomide, Tecfidera, platform injectable therapies

Key companies: Biogen, Novartis, Roche, Sandoz / Polpharma Biologics, TG Therapeutics / Neuraxpharm

Key analyses:

  • Factors influencing disease management and treatment decisions.
  • Drivers and constraints of treatment selection.
  • Physician-reported treatment practices and brand-level patient shares.
  • Rationale for changes in treatment approach.
  • Physician insight on persistency and compliance.
  • Physician-reported recent / anticipated changes in brand usage or treatment approach.

Related Market Assessment Reports

Report
Insomnia – Current Treatment – Treatment Algorithms: Claims Data Analysis – Insomnia (US)
Insomnia is a prevalent sleep disorder characterized by daytime dysfunction resulting from one or more sleep problems. The treatment of insomnia is highly individualized, and physicians consider…
Report
Psoriasis – Geographic Focus: China – Psoriasis | China In-Depth | China | 2025
Psoriasis is a chronic dermatologic condition with rising prevalence in China, particularly in urban areas where heightened awareness and improved access to care have led to higher diagnosis rates…
Report
Chronic Kidney Disease – Geographic Focus: China – Chronic Kidney Disease – China In-Depth (China)
Chronic kidney disease (CKD) is an irreversible condition requiring lifelong management. In China, CKD is notably widespread, particularly among older adults and those with chronic risk factors…
Report
Ovarian Cancer – Landscape & Forecast – Disease Landscape & Forecast (G7)
The treatment landscape for ovarian cancer has been revolutionized by the angiogenesis inhibitor bevacizumab and the PARP inhibitors olaparib (Lynparza; AstraZeneca / Merck & Co.), niraparib (…
Report
Type 2 Diabetes – Geographic Focus: China – Type 2 Diabetes – China In-Depth (China)
In China, type 2 diabetes (T2D) continues to be a leading public health concern, with the highest global prevalence. Biguanides continue to dominate the market, but the use of SGLT-2 inhibitors and…